You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
Brief News on Innovation
Company News Brief News on Innovation
Brief News on Innovation
NMPA APPROVAL FOR REGISTRATION APPLICATION OF DCwire™ MICRO GUIDEWIRE
2023.07.07
NMPA APPROVAL FOR REGISTRATION APPLICATION OF DCwire™ MICRO GUIDEWIRE

This announcement is made by Peijia Medical Limited (the “Company”, together wit···
First Asian Commercial Implants with the Trilogy Heart Valve System performed by Dr. Michael Lee and His Team in Queen Elizabeth Hospital in Hong Kong
2023.05.18
First Asian Commercial Implants with the Trilogy Heart Valve System perform···

On May 12th, 2023, Dr. Michael Lee and his team from the Cardiology Department o···
FIRST PATIENT ENROLLMENT IN THE MULTI-CENTER REGISTRATION CLINICAL TRIAL OF GeminiOne® TRANSCATHETER EDGE-TO-EDGE REPAIR SYSTEM IN CHINA
2022.12.04
FIRST PATIENT ENROLLMENT IN THE MULTI-CENTER REGISTRATION CLINICAL TRIAL OF···

FIRST PATIENT ENROLLMENT IN THE MULTI-CENTER REGISTRATION CLINICAL TRIAL OF Gem···
FIRST PATIENT IMPLANT IN THE FIRST-IN-MAN CLINICAL TRIAL OF THE MonarQ TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM IN THE WORLD
2022.11.25
FIRST PATIENT IMPLANT IN THE FIRST-IN-MAN CLINICAL TRIAL OF THE MonarQ TRAN···

FIRST PATIENT IMPLANT IN THE FIRST-IN-MAN CLINICAL TRIAL OF THE MonarQ TRANSCAT···
FIRST PATIENT IMPLANT IN MULTI-CENTER REGISTRATION CLINICAL TRIAL OF PEIJIA HighLife® TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM IN CHINA
2022.11.14
FIRST PATIENT IMPLANT IN MULTI-CENTER REGISTRATION CLINICAL TRIAL OF PEIJIA···

FIRST PATIENT IMPLANT IN MULTI-CENTER REGISTRATION CLINICAL TRIAL OF PEIJIA Hig···
ONE-YEAR CLINICAL FOLLOW-UP RESULTS OF TaurusNXT® WERE RELEASED AT CHINA STRUCTURAL WEEK 2024
2024.10.18
ONE-YEAR CLINICAL FOLLOW-UP RESULTS OF TaurusNXT® WERE RELEASED AT CHINA S···

From October 9-16, 2024, China Structural Week 2024 was grandly held. TaurusNXT···
Peijia Medical Fluxcap® Balloon Guide Catheter Obtained NMPA Approval
2022.06.09
Peijia Medical Fluxcap® Balloon Guide Catheter Obtained NMPA Approval

On June 8, 2022, Peijia Medical received the approval from the National Medical ···
Peijia Medical Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Dilation Catheter Obtained NMPA Approval
2022.05.24
Peijia Medical Tethys AS® Aspiration Catheter and Fastunnel® Delivery Ballo···

Peijia Medical Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Di···
NMPA Approval for Registration Application of Syphonet®️ Stent Retriever
2022.02.17
NMPA Approval for Registration Application of Syphonet®️ Stent Retriever

On February 11, 2022, Peijia Medical Limited (the “Company”) received the approv···
The First Clinical Case using HighLife Transseptal Mitral Valve Replacement Technology was successfully carried out in Asia
2022.01.08
The First Clinical Case using HighLife Transseptal Mitral Valve Replacement···

On December 22, 2021, the first clinical case using HighLife transseptal mitral ···
Peijia Medical Announces First Patient Treatment in the Clinical Trial of its Innovative Non-implant
2021.11.01
Peijia Medical Announces First Patient Treatment in the Clinical Trial of i···

A major breakthrough in interventional therapy for heart valve disease and an in···
Peijia Medical Announces First Patient Implant in the Clinical Trial of its Third-Generation Transca
2021.09.14
Peijia Medical Announces First Patient Implant in the Clinical Trial of its···

Peijia Medical today announced the initiation of its multi-center clinical trial···
Home < ···23456 > Last
Top